DDX53 and colorectal carcinoma: To further confirm the role of STAT3 activation in promoting CRC-EVs-mediated macrophage efferocytosis, we treated MFGE8-knockout CRC-EVs (including CT26-MFGE8KOEVs and MC38-MFGE8KOEVs) with the STAT3 agonist Colivelin.